News Breaks |
|
|
| February 20, 2013 |
| 07:37 EDT |  | AEZS | Aeterna Zentaris announces first patient treated for Phase 2 trial with AEZS-108
Aeterna Zentaris announced that a first patient has been treated for the randomized Phase 2 trial in chemotherapy refractory triple-negative luteinizing hormone-releasing hormone receptor-positive metastatic breast cancer, with the company's targeted doxorubicin peptide conjugate, AEZS-108. |
|
|
News For AEZS From The Last 14 Days Check below for free stories on AEZS the last two weeks. |
|
|
| May 22, 2013 |
| 07:35 EDT |  | AEZS | Bloom Burton & Co. to host a conference
 Subscribe for More Information |
|
| May 21, 2013 |
| 16:58 EDT |  | AEZS | Aeterna Zentaris may sell up to 2.5M common shares up to $4.6M
Aeterna Zentaris announced that it has entered into an at "At-the-Market" Issuance agreement with MLV & Co. under which the company may sell up to a maximum of 2.5M of its common shares through ATM issuances up to an aggregate amount of $4.6M. The common shares will be sold at market prices prevailing at the time of the sale of common shares. |
|
|
|
|
|
